Morphological Predictive Features on Spectral-Domain Optical Coherence Tomography for Visual Outcomes in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab

Table 1

Patient demographic and baseline characteristics.

	Group		P-value
	“Responders”	“Nonresponders”
	(n = 40)	(n = 24)
Age at first injection,; years (mean ± SD)	81.3 ± 2.6	76.2 ± 4.2	0.30
Sex, n (%)
Male	15 (37.5)	6 (25.0)	0.33
Female	25 (62.5)	18 (75.0)	0.29
Best-corrected visual acuity, ETDRS (mean ± SD)	58 ± 8.0	61 ± 7.2	0.27
Central retinal thickness,; μm (mean ± SD)	368.7 ± 87.2	376.0 ± 141.1	0.80
CNV type on FA, n (%)
Type 1 CNV	20 (50.0)	16 (66.7)	0.37
Type 2 CNV	10 (25.0)	4 (16.7)	0.28
Type 3 CNV	5 (12.5)	2 (8.3)	0.42
Type 4 CNV	5 (12.5)	2 (8.3)	0.42

n, number; SD, standard deviation; y, years; ETDRS, Early Treatment Diabetic Retinopathy Study; CNV, choroidal neovascularization; FA, fluorescein angiography; Type 1 CNV, sub-RPE (retinal pigment epithelium) CNV; Type 2, subretinal CNV; Type 3, intraretinal CNV; Type 4, Mixed CNV.